Abstract 3958
Background
Digestive Cancers Europe (DiCE), a European digestive cancer patients umbrella organization, planned and executed a cross-sectional survey in 15 European countries on the Unmet Needs of Patients Living with mCRC to examine the challenges and needs and QoL of those living with mCRC.
Methods
DiCE partner organisations, together with clinicians and nurses recruited patients for the survey (paper-based and online). The survey included demographics, data on discovery of the disease, diagnosis and treatment and the EORTC QLQ-C30 and CR29. Single data entry from the paper surveys was done by DiCE. Descriptive statistics and regression analyses were run to examine the global QoL score, function (F) - and symptom-specific scores, the item on financial difficulties and CR29 scores and their association with patient and disease characteristics and care setting by country and overall.
Results
883 surveys from Austria, Belgium, Cyprus (CY), Germany, Hungary (HU), Italy, Netherlands (NL), Norway, Serbia (RS), Poland, Spain (SP), UK, Portugal, Turkey and Ireland were collected. Only 8 countries with samples over 35 were analyzed on their own. Completion rates across QoL items were high (91-94%). Large variation across countries have been observed in mean scores (Table). Eastern vs Western Europe contrasted sharply, with Serbia and Poland reporting lower functional and much higher symptom scores for fatigue, nausea, vomiting, pain and insomnia. Regression analyses indicated that after adjustment for age, gender and care setting country differences remained significant. Patterns in results across dimensions of EORTC QLQ-CR29 were similar.Table:
659P
Mean (SD) | Global QoL | Physical F | Role F | Emotional F | Cognitive F | Social F |
---|---|---|---|---|---|---|
Lowest score | 55.94 (21.10) RS | 69.06 (23.93) CY | 62.58 (34.73) CY | 53.51 (28.35) RS | 71.31 (24.6) RS | 54.04 (25.91) RS |
Highest score | 69.26 (20.68) HU | 84.29 (17.87) SP | 81.76 (25.41) SP | 80.92 (21.04) NL | 87.86 (19.13) HU | 80.91 (24.63) HU |
OVERALL | 62.02 (21.75) | 74.25 (20.85) | 71.41 (28.76) | 68.25 (26.41) | 78.58 (23.39) | 68.56 (28.99) |
Conclusions
Country specific mean QoL scores in all function/symptom dimensions varied greatly across countries. This study indicates that care setting and other country-specific circumstances have important associations to QoL. Real-world mCRC patients’ QoL may be lower than those recruited in clinical trials.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
EuropaColon / Digestive Cancers Europe.
Funding
Merck, BMS, Sandoz and Sirtex.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5773 - A prospective study of diffusion-weighted magnetic resonance imaging for predicting outcome following chemoradiotherapy, in squamous cell carcinomas of the anus.
Presenter: Rebecca Muirhead
Session: Poster Display session 2
Resources:
Abstract
4581 - Timing to achieve complete response (CR) after definitive chemoradiotherapy (ChRT) in patients with squamous cell carcinoma of the anal (SCCAC) with and without HIV infection: a multicenter retrospective study
Presenter: Marcos Camandaroba
Session: Poster Display session 2
Resources:
Abstract
1712 - Planned organ preservation for T2 T3 M0 rectal adenocarcinoma. A possible option using chemoradiotherapy (CRT) and Contact X-ray Brachytherapy (CXB). A French multicenter study.
Presenter: Jean-Pierre Gérard
Session: Poster Display session 2
Resources:
Abstract
4639 - A Phase 1b Study of E7046 (AN0025) in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative Treatment of Rectal Cancer
Presenter: Lucjan Wyrwicz
Session: Poster Display session 2
Resources:
Abstract
2310 - Upfront radical surgery with total mesorectal excision (TME) versus preoperative chemoradiotherapy followed by TME in clinical stage II/III patients with rectal cancer: a propensity score analysis
Presenter: Ahrong Ham
Session: Poster Display session 2
Resources:
Abstract
2747 - Neoadjuvant chemoradiotherapy with/without lateral lymph node dissection for low rectal cancer: Which patients can benefit?
Presenter: Daisuke Nishizaki
Session: Poster Display session 2
Resources:
Abstract
2877 - The impact of completeness of chemotherapy on the efficacy of irinotecan in the preoperative chemoradiotherapy of locally advanced rectal cancer.
Presenter: Jingwen Wang
Session: Poster Display session 2
Resources:
Abstract
3050 - Feasibility of robot-assisted surgery in elderly patients with rectal cancer
Presenter: Wei-Chih Su
Session: Poster Display session 2
Resources:
Abstract
4109 - Feasibility of chemoradiotherapy in rectal cancer patients with peritumoral abscesses and fistulas: a case-control non-inferiority trial
Presenter: Valerii Ivanov
Session: Poster Display session 2
Resources:
Abstract
4813 - Differential of the nutritional index before and after neoadjuvant chemoradiotherapy as a prognostic factor of recurrence in patients with locally advanced adenocarcinoma of the rectum
Presenter: Leslie Navia-Ortuño
Session: Poster Display session 2
Resources:
Abstract